A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

NCT05363722 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: IBI310（0.5mg/kg）
DRUG: IBI310（0.3mg/kg）
DRUG: sintilimab
DRUG: bevacizumab

Sponsor

Shanghai Zhongshan Hospital